Journal article
Authors list: Schütz, H; Erdmann, F; Risse, M; Weiler, G
Publication year: 2002
Pages: 716-719
Journal: Arzneimittel-Forschung
Volume number: 52
Issue number: 9
ISSN: 0004-4172
eISSN: 1616-7066
Publisher: Thieme Publishing
Abstract:
This study deals with the question of whether apomorphine (CAS 314-19-2; e.g. In Ixense(R)) and its metabolites or decomposition products interfere with the specificity of immunochemical screening tests (immunoassays) for legal and illicit drugs. It was the result of the investigations that after the therapeutic use of apomorphine no relevant false-positive screening findings were observed with the CEDIA (cloned enzyme donor immuno assay) and FPIA (fluorescence polarisation immuno assay) tests, which are commonly encountered in drug-screening programs, when using recommended cut-off values for urine.
Citation Styles
Harvard Citation style: Schütz, H., Erdmann, F., Risse, M. and Weiler, G. (2002) Studies of interferences of apomorphine and its metabolites or decomposition products with immunochemical screening tests for legal and illicit drugs after therapeutic doses of apomorphine, Arzneimittel-Forschung, 52(9), pp. 716-719
APA Citation style: Schütz, H., Erdmann, F., Risse, M., & Weiler, G. (2002). Studies of interferences of apomorphine and its metabolites or decomposition products with immunochemical screening tests for legal and illicit drugs after therapeutic doses of apomorphine. Arzneimittel-Forschung. 52(9), 716-719.
Keywords
apomorphine; CAS 314-19-2; cloned enzyme donor immuno assay; ERECTILE; fluorescence polarisation immuno assay; immunochemical screening tests, specificity; Ixense (R); SL
